OR WAIT null SECS
Salt Lake City-Lifetree Clinical Research, one of the largest specialized clinical research organizations in the Western region of the United States, is expanding its services to include a broader range of central nervous system-related investigations with the formation of Lifetree Center for Neuroscience Research.
In conjunction with the formation of the Lifetree Center for Neuroscience Research, Lifetree Clinical Research has added Dr. Noel C. Gardner, a psychiatrist, and Dr. Daniel Brennan Vine, a neurologist, to its staff.
Lifetree Clinical Research supports the pharmaceutical, medical device and biotechnology industries through site services, clinical trials management including drug development, regulatory support, medical monitoring, data management, statistical analysis, medical writing, project management, recruitment and monitoring.
According to Lifetree Clinical Research Founder and CEO Alice Jackson, “Our company will now be covering all areas of central nervous system drug
development. By broadening our scope of services, we’ll be able to conduct important research in such areas as obesity, anxiety, depression, bi-polar,
migraine, Parkinson’s disease, seizures, epilepsy, Alzheimer’s and dementia, to name a few.”
Prior to joining Lifetree, Gardner was part of the adult psychiatry clinical staff at Intermountain Health Care/Alta View Center for Counseling. In 2004, he founded the Institute of Neuroscience Research, Inc. in Salt Lake City. Gardner has a long-standing relationship with the University of Utah, and has taught the undergraduate medical curriculum, the graduate psychiatry curriculum, and the graduate medicine curriculum since 1988. He was a full-time faculty member and chief of the Division of Consultation Psychiatry at the University of Utah from 1988 to 2002. During that time, he rose through the tenure and promotion process to become a full clinical professor. He was also appointed as an adjunct professor in the university’s Department of Psychiatry and Department of Family and Preventative Medicine in 2003. Gardner earned his M.D from Loma Linda University in Loma Linda, Calif. in 1984. He completed his internship with Harbor-UCLA Medical Center in 1985 and his residency with UCLA Neuropsychiatric Institute in 1988. He also served as chief resident of the UCLA Neuropsychiatric Institute’s Geriatric Psychiatry Unit from 1987 to 1988. Since 2000, Gardner has served on national advisory boards for Zyprexa (Eli Lilly), Prozac Weekly (Eli Lilly), Neuroscience Outcomes Research (Eli Lilly), Cross-Product Applications in Bipolar Disorder (Eli Lilly), Pharmacogenomics in Clinical Practice (Roche Diagnostics), Duloxetine/Cymbalta (Eli Lilly), Symbyax (Eli Lill) and Takeda
Pharmaceuticals/S. Lundbeck Pharmaceuticals. Throughout his career, he has also served as a forensic psychiatrist on numerous high-profile criminal and
civil cases, including cases involving psychopharmacology-related litigation.
Since 1982, Vine has been an investigator in 50 industry-sponsored clinical trials. In addition to his work with Lifetree Clinical Research, he will maintain his position as a principal investigator with Utah-based Pivotal Research Centers. He has been with Pivotal Research Centers since 2004. Since 1992, he has maintained a private practice and been a staff physician at Salt Lake Regional Medical Center. Since 1993, he has also been a staff physician at Davis Hospital in Layton, Utah. Vine received his M.D. from Baylor College of Medicine in Houston, Texas.